

CITATION REPORT

List of articles citing

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration

DOI: 10.1016/j.opthta.2012.10.014
Ophthalmology, 2013, 120, 1046-56.

Source: <https://exaly.com/paper-pdf/55912991/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
405	Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration. 2013 , 30, 1111-27		28
404	Vascular endothelial growth factor and its inhibitor in age-related macular degeneration. 2013 , 3, 128-133		2
403	Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. <i>Ophthalmology</i> , 2013 , 120, 1945-6.e1	7.3	14
402	Headache or eye pain as the presenting feature of uveal melanoma. <i>Ophthalmology</i> , 2013 , 120, 1946-7.e23		9
401	Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. 2013 , 2013, 943409		49
400	Proactive versus reactive anti-VEGF therapies for neovascular age-related macular degeneration: pros and cons. 2013 , 8, 321-326		1
399	One-year results of intravitreal ranibizumab 0.5 versus 2.0 mg for the treatment of exudative age-related macular degeneration. 2013 , 8, 347-350		
398	Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. 2013 , 7, 1849-58		43
397	Critical appraisal of ranibizumab in the treatment of diabetic macular edema. 2013 , 7, 1257-67		18
396	Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. 2014 , 45, 526-33		27
395	A delphi study to detect deficiencies and propose actions in real life treatment of neovascular age-related macular degeneration. 2014 , 2014, 595132		7
394	A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. 2014 , 2014, 857148		20
393	Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration. 2014 , 8, 717-23		10
392	Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema. 2014 , 8, 1611-21		74
391	Introduction. Treatment paradigms within the use of anti-VEGF agents. 2014 , 98 Suppl 1, i1-2		1
390	Reducing the clinical burden of ranibizumab treatment for neovascular age-related macular degeneration using an individually planned regimen. 2014 , 98, 1192-6		45
389	Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). 2014 , 98, 951-5		65

388	Ranibizumab treatment in age-related macular degeneration: a meta-analysis of one-year results. 2014 , 231, 427-31		8
387	Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab. 2014 , 39, 234-9		14
386	No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting. 2014 , 34, 951-7		47
385	Sensitivity of fluid detection in patients with neovascular amd using spectral domain optical coherence tomography high-definition line scans. 2014 , 34, 1163-6		17
384	Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration. 2014 , 157, 825-833.e1		57
383	Current Strategies for the Management of Treatment-Resistant Neovascular Age-Related Macular Degeneration. 2014 , 2, 6-13		3
382	[Pharmacokinetics of intravitreally administered VEGF inhibitors]. 2014 , 111, 113-20		12
381	Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials. <i>Ophthalmology</i> , 2014 , 121, 2193-203.e1-7	7-3	47
380	Effects of ranibizumab on the extracellular matrix production by human Tenon's fibroblast. 2014 , 127, 236-42		6
379	Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2014 , 121, 2181-92	7-3	207
378	A safety evaluation of ranibizumab in the treatment of age-related macular degeneration. 2014 , 13, 1259-70		12
377	Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration. 2014 , 92, 713-23		28
376	Bimonthly injections of ranibizumab for age-related macular degeneration. 2014 , 252, 1545-51		9
375	Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD. 2014 , 49, 431-5		7
374	Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). 2014 , 98, 1144-67		308
373	Safety monitoring of ophthalmic biologics: a systematic review of pre- and postmarketing safety data. 2014 , 30, 729-51		15
372	Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2014 , 121, 1237-45	7-3	121
371	Antivascular endothelial growth factor therapies for neovascular age-related macular degeneration: Search for the optimized treatment regimen. 2014 , 4, 3-8		2

370	A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. 2014 , 98 Suppl 1, i22-27	54
369	Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries. 2014 , 158, 537-43.e2	46
368	Stereotactic low voltage x-ray radiotherapy for treating neovascular age-related macular degeneration. 2014 , 9, 153-158	
367	High-dose ranibizumab monotherapy for neovascular polypoidal choroidal vasculopathy in a predominantly non-Asian population. 2015 , 29, 1427-37	6
366	Neovascular Age-Related Macular Degeneration. 2016 , 55, 125-36	38
365	Incidence of outer retinal tubulation in ranibizumab-treated age-related macular degeneration. 2015 , 35, 1166-72	13
364	REFRACTORY INTRARETINAL OR SUBRETINAL FLUID IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIZUBIMAB: Functional and Structural Outcome. 2015 , 35, 1195-201	42
363	RELATIONSHIP BETWEEN VISUAL PROGNOSIS AND DELAY OF INTRAVITREAL INJECTION OF RANIBIZUMAB WHEN TREATING AGE-RELATED MACULAR DEGENERATION. 2015 , 35, 1331-8	16
362	VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. 2015 , 35, 1750-6	14
361	Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration. 2015 , 9, 1315-20	5
360	A single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysis. 2015 , 9, 1759-66	27
359	Two week, OCT-based follow-up as guidance for retreatment with ranibizumab for CNV apparently refractory to therapy. 2015 , 25, 235-40	2
358	Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements. 2015 , 4, 6	28
357	22 anti-vascular endothelial growth factor (anti-VEGF) therapy Optical Coherence Tomography and Anti-Vascular Endothelial Growth Factor Therapy. 2015 ,	
356	Current perspectives on ranibizumab. 2015 , 9, 533-42	14
355	Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis. 2015 , 9, 5397-405	42
354	Relationship of retinal morphology and retinal sensitivity in the treatment of neovascular age-related macular degeneration using aflibercept. 2014 , 56, 1158-67	22
353	Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. 2015 , 10, e0133968	40

352	Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. 2015 , 10, e0137866		14
351	Anti-VEGF Therapy and the Retina: An Update. 2015 , 2015, 627674		72
350	Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration. <i>Ophthalmology</i> , 2015 , 122, 803-8	7-3	91
349	Scatter Photocoagulation Does Not Reduce Macular Edema or Treatment Burden in Patients with Retinal Vein Occlusion: The RELATE Trial. <i>Ophthalmology</i> , 2015 , 122, 1426-37	7-3	78
348	Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration. <i>Ophthalmology</i> , 2015 , 122, 1212-9	7-3	116
347	Refractory subretinal fluid in patients with neovascular age-related macular degeneration treated with intravitreal ranibizumab: visual acuity outcome. 2015 , 253, 1211-6		19
346	Two-year outcome of an observe-and-plan regimen for neovascular age-related macular degeneration: how to alleviate the clinical burden with maintained functional results. 2015 , 29, 342-9		21
345	Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. 2015 , 99, 220-6		320
344	Advances in pharmacotherapy for wet age-related macular degeneration. 2015 , 16, 1769-81		23
343	Functional Characterization of AAV-Expressed Recombinant Anti-VEGF Single-Chain Variable Fragments In Vitro. 2015 , 31, 269-76		4
342	One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD. 2015 , 99, 618-23		17
341	Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. 2015 , 159, 915-24.e2		125
340	Comparing different dosing regimens of bevacizumab in the treatment of neovascular macular degeneration: study protocol for a randomised controlled trial. 2015 , 16, 85		7
339	A model of the ocular pharmacokinetics involved in the therapy of neovascular age-related macular degeneration with ranibizumab. 2015 , 99, 1554-9		16
338	Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. 2015 , 159, 1100-1114.e1		54
337	Association of Baseline Characteristics and Early Vision Response with 2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT). <i>Ophthalmology</i> , 2015 , 122, 2523-31.e1	7-3	67
336	Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity. 2015 , 233, 27-34		4
335	Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. 2015 , 18, 397-432		26

334	Ranibizumab vs. aflibercept for wet age-related macular degeneration: network meta-analysis to understand the value of reduced frequency dosing. 2015 , 31, 2031-42		16
333	Baseline Predictors of 12-Month Treatment Response to Ranibizumab in Patients With Wet Age-Related Macular Degeneration. 2015 , 160, 1014-1023.e2		41
332	Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results. <i>Ophthalmology</i> , 2015 , 122, 2514-22	7-3	177
331	Response-based individualized medicine for neovascular age-related macular degeneration. 2015 , 10, 105-112		2
330	Scheduled versus Pro Re Nata Dosing in the VIEW Trials. <i>Ophthalmology</i> , 2015 , 122, 2497-503	7-3	28
329	Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration. 2015 , 29, 80-7		17
328	Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. <i>Ophthalmology</i> , 2015 , 122, 399-406	7-3	46
327	A retrospective study of the real-life utilization and effectiveness of ranibizumab therapy for neovascular age-related macular degeneration in the UK. 2016 , 10, 87-96		18
326	Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration. 2016 , 57, OCT14-26		42
325	Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis. 2016 , 79, 384-389		8
324	High Dose Intravitreal Bevacizumab for Refractory Pigment Epithelial Detachment in Age-related Macular Degeneration. 2016 , 30, 265-71		7
323	Epidemiological and Clinical Baseline Characteristics as Predictive Biomarkers of Response to Anti-VEGF Treatment in Patients with Neovascular AMD. 2016 , 2016, 4367631		21
322	Effect of Fluid Status at Week 12 on Visual and Anatomic Outcomes at Week 52 in the VIEW 1 and 2 Trials. 2016 , 47, 238-44		6
321	Biomaterials for intraocular sustained drug delivery. 2016 , 131-147		
320	Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. 2016 , 10, 1857-67		111
319	CONVERSION TO AFLIBERCEPT THERAPY VERSUS CONTINUING WITH RANIBIZUMAB THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DEPENDENT ON MONTHLY RANIBIZUMAB TREATMENT. 2016 , 36, 53-8		20
318	PROGRESSION OF MACULAR ATROPHY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDERGOING ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 2016 , 36, 1843-50		43
317	Systemic safety of intravitreal anti-vascular endothelial growth factor agents in age-related macular degeneration. 2016 , 27, 224-43		9

316	Characteristics and Predictors of Early and Delayed Responders to Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Retrospective Analysis from the ANCHOR, MARINA, HARBOR, and CATT Trials. 2016 , 236, 193-200		10
315	Key drivers of visual acuity gains in neovascular age-related macular degeneration in real life: findings from the AURA study. 2016 , 100, 1623-1628		70
314	Changing from a pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration. 2016 , 100, 1341-5		31
313	Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision. 2016 , 100, 1052-7		10
312	[Management algorithm of age-related macular degeneration with aflibercept: Real-life application]. 2016 , 39, 872-879		
311	HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies. 2016 , 19, 257-73		17
310	Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts. 2016 , 33, 715-26		9
309	Anti-Angiogenic Therapy in Ophthalmology. 2016 ,		3
308	Anti-vascular Endothelial Growth Factor (VEGF) Treatment in Neovascular Age-Related Macular Degeneration: Outcomes and Outcome Predictors. 2016 , 31-65		
307	In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device. 2016 , 6, 771-780		17
306	Determinants of visual acuity outcomes in eyes with neovascular AMD treated with anti-VEGF agents: an instrumental variable analysis of the AURA study. 2016 , 30, 1063-71		26
305	Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study. <i>Ophthalmology</i> , 2016 , 123, 2545-2553	7-3	49
304	Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option. 2016 , 30, 1531-1541		9
303	Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. <i>Ophthalmology</i> , 2016 , 123, 2213-24	7-3	29
302	Real world evidence of use of anti-VEGF therapy in Denmark. 2016 , 32, 1943-1950		19
301	Anti-Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease: From Bench to Bedside. <i>Ophthalmology</i> , 2016 , 123, S78-S88	7-3	73
300	CORRELATION OF SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY AND CLINICAL ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2016 , 36, 2265-2273		29
299	The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration—a phase IV randomised clinical trial with ranibizumab: the FLUID study. 2016 , 16, 31		54

298	Contribution of Antibody Hydrodynamic Size to Vitreal Clearance Revealed through Rabbit Studies Using a Species-Matched Fab. 2016 , 13, 2996-3003		50
297	RETROSPECTIVE REVIEW OF LUCENTIS "TREAT AND EXTEND" PATTERNS AND OUTCOMES IN AGE-RELATED MACULAR DEGENERATION. 2016 , 36, 272-8		7
296	Choroidal Thickness Changes in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy: A 12-Month Prospective Study. 2016 , 164, 128-36.e1		59
295	Ten years of anti-vascular endothelial growth factor therapy. 2016 , 15, 385-403		507
294	First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016 , 123, 337-343	7:3	72
293	Ranibizumab for the treatment of wet AMD: a summary of real-world studies. 2016 , 30, 270-86		73
292	[Evaluation of the efficacy of aflibercept's in the treatment of neovascular age-related macular degeneration in treatment-naive and switched patients. Report of 86 cases]. 2016 , 39, 255-60		4
291	Treatment for neovascular age related macular degeneration: The state of the art. 2016 , 787, 78-83		17
290	Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study. <i>Ophthalmology</i> , 2016 , 123, 1080-9	7:3	80
289	A Phase 1 Study of Intravitreal E10030 in Combination with Ranibizumab in Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2016 , 123, 78-85	7:3	63
288	Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues. 2016 , 15, 75-87		8
287	Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. <i>Ophthalmology</i> , 2016 , 123, 60-9	7:3	66
286	A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration. 2016 , 50, 1-24		177
285	Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study. 2017 , 95, e67-e72		44
284	Randomized Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: 2-Year Results of the TREX-AMD Study. 2017 , 1, 314-321		56
283	Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. 2017 , 7, 44020		16
282	The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis. 2017 , 34, 611-619		16
281	Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials. 2017 , 17, 7		28

280 Targeting Vascular Endothelial Growth Factor. **2017**, 99-139

279 Neovascular Age-Related Macular Degeneration. **2017**, 183-203

278 Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases. **2017**, 180, 8-17 41

277 SHORT-TERM SAFETY OF 2 MG INTRAVITREAL ZIV-AFLIBERCEPT. **2017**, 37, 1859-1865 13

276 [Individualized management of patients with exudative AMD, IOI protocol: Injection-observational-individualization]. **2017**, 40, 169-176 2

275 Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study. **2017**, 1, 304-313 20

274 A Review of Ranibizumab for the Treatment of Diabetic Retinopathy. **2017**, 6, 33-47 27

273 Diabetic Retinopathy. **2017**, 0

272 Ranibizumab for vascularized pigment epithelial detachment: 1-year anatomic and functional results. **2017**, 255, 743-751 8

271 [Management of wet AMD in France in 2015]. **2017**, 40, 723-730 2

270 Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections. **2017**, 238, 217-225 7

269 Current Best Clinical Practices Management of Neovascular AMD. **2017**, 1, 294-297 8

268 The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. **2017**, 95, 1-9 16

267 Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. **2017**, 31, 1697-1706 50

266 [Real life visual and anatomic outcomes of aflibercept treatment for treatment-naive patients with exudative age-related macular degeneration]. **2017**, 40, 270-278 5

265 Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody RG7716 for Neovascular Age-Related Macular Degeneration. **2017**, 1, 474-485 42

264 Effektivität und Frequenz der intravitrealen Injektionstherapie bei neovaskulärer altersabhängiger Makuladegeneration im Krankenhaus Hietzing im internationalen Vergleich. **2017**, 31, 187-193

263 NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators. **2017**, 37, 257-264 4

262	Advancements in Understanding Immunogenicity of Biotherapeutics in the Intraocular Space. 2017 , 19, 1656-1668		18
261	[Eye Drops Instead of Intravitreal Injections? The Dream of Treating Macular Diseases by Topically Administered Drugs]. 2017 , 234, 1088-1093		1
260	OUTCOMES OF AN INTRAVITREAL INJECTION CLINIC. 2017 , 37, 1371-1376		8
259	Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial. <i>Ophthalmology</i> , 2017 , 124, 224-234	7-3	81
258	Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial. <i>Ophthalmology</i> , 2017 , 124, 215-223	7-3	40
257	Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis. 2017 , 96, e9345		4
256	Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel. 2017 , 6, 296-302		12
255	The ARMOUR Study: Anti-VEGF in Neovascular AMD--Our Understanding in a Real-World Indian Setting. 2017 , 6, 488-492		3
254	Recent developments in age-related macular degeneration: a review. 2017 , 12, 1313-1330		168
253	Investigation of time to first presentation and extrahospital factors in the treatment of neovascular age-related macular degeneration: a retrospective cross-sectional study. 2017 , 7, e017771		10
252	Development of a Sustainable Release System for a Ranibizumab Biosimilar Using Poly(lactic-co-glycolic acid) Biodegradable Polymer-Based Microparticles as a Platform. 2017 , 40, 145-150		17
251	An Overview of the Fovista and Rinucumab Trials and the Fate of Anti-PDGF Medications. 2017 , 48, 100-104		45
250	Prediction of Anti-VEGF Treatment Requirements in Neovascular AMD Using a Machine Learning Approach. 2017 , 58, 3240-3248		85
249	Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial. 2017 , 11, 223-231		9
248	Pro re Nata versus Bimonthly Regimen in Exudative AMD Treated with Aflibercept: 1-year Results. 2017 , 1, oapoc.0000021		0
247	The study of intravitreal drug pharmacokinetics: does it matter? and if so, how?. 2018 , 14, 5-7		3
246	Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2018 , 125, 878-886	7-3	63
245	Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness. 2018 , 96 Suppl A109, 1-46		2

244	An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. 2018 , 256, 963-973		8
243	Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. 2018 , 2, 645-653		36
242	Evolution of Intravitreal Therapy for Retinal Diseases-From CMV to CNV: The LXXIV Edward Jackson Memorial Lecture. 2018 , 191, xli-lviii		19
241	The Real-World Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. <i>Ophthalmology</i> , 2018 , 125, 676-682	73	34
240	Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW Study. 2018 , 37, 596-601		6
239	One-Year Effectiveness Study of Intravitreal Ranibizumab in Wet (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis. 2018 , 38, 197-204		4
238	Risk Factors for Discontinuation of Treatment for Neovascular Age-Related Macular Degeneration. 2018 , 25, 176-182		10
237	Efficacy and Safety of Lampalizumab for Geographic Atrophy Due to Age-Related Macular Degeneration: Chroma and Spectri Phase 3 Randomized Clinical Trials. 2018 , 136, 666-677		166
236	The Systemic Safety of Ranibizumab in Patients 85 Years and Older with Neovascular Age-Related Macular Degeneration. 2018 , 2, 667-675		5
235	TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2018 , 38, 20-28		58
234	BIOMARKERS OF NEOVASCULAR ACTIVITY IN AGE-RELATED MACULAR DEGENERATION USING OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 2018 , 38, 220-230		84
233	Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. 2018 , 23, 127-140		46
232	Machine Learning to Analyze the Prognostic Value of Current Imaging Biomarkers in Neovascular Age-Related Macular Degeneration. 2018 , 2, 24-30		81
231	PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis. 2018 , 38, 1274-1280		32
230	[Volumetric analysis of vascularized pigment epithelium detachment in AMD: post hoc analysis of the RECOVER study]. 2018 , 115, 754-760		0
229	Recurrence Rate of Choroidal Neovascularization in Neovascular Age-Related Macular Degeneration Managed with a Treat-Extend-Stop Protocol. 2018 , 2, 225-230		29
228	Comparison of Short-Term Choroidal Thickness and Retinal Morphological Changes after Intravitreal Anti-VEGF Therapy with Ranibizumab or Aflibercept in Treatment-Naive Eyes. 2018 , 43, 391-396		15
227	Aflibercept for Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in Germany: Twelve-Month Outcomes of PERSEUS. 2018 , 2, 539-549		28

226	Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article. 2018 , 34, 298-308	5
225	Age-related macular degeneration: using morphological predictors to modify current treatment protocols. 2018 , 96, 120-133	34
224	Systemic Safety of Ranibizumab for Neovascular Age-Related Macular Degeneration: Do Ophthalmologists Still Have to Sweat the Small Stuff?. 2018 , 2, 1085-1086	
223	Real-life experience of ranibizumab therapy for neovascular age-related macular degeneration from Turkey. 2018 , 11, 267-273	2
222	Functional Characterization of Abicipar-Pegol, an Anti-VEGF DARPIn Therapeutic That Potently Inhibits Angiogenesis and Vascular Permeability. 2018 , 59, 5836-5846	43
221	Pharmacological Management of Diabetic Macular Edema in Real-Life Observational Studies. 2018 , 2018, 8289253	30
220	Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration. 2018 , 59, 1033-1044	9
219	Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial. 2018 , 192, 84-90	3
218	The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration-A cost-effectiveness analysis from a societal perspective. 2018 , 13, e0197670	49
217	Optical Coherence Tomography Angiography to Distinguish Changes of Choroidal Neovascularization after Anti-VEGF Therapy: Monthly Loading Dose versus Pro Re Nata Regimen. 2018 , 2018, 3751702	15
216	Neovascular Age-Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect. 2018 , 7, 660-669	6
215	Artificial intelligence in retina. 2018 , 67, 1-29	250
214	Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration. 2018 , 24, S3-S15	59
213	Usability of the Ranibizumab 0.5 mg Prefilled Syringe: Human Factors Studies to Evaluate Critical Task Completion by Healthcare Professionals. 2018 , 72, 411-419	1
212	Age-Related Macular Degeneration. 2018 , 35-70	
211	Systemic Safety in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration: A Patient-Level Pooled Analysis. 2018 , 2, 1087-1096	9
210	[Analysis of real-life data on treatment quality in patients with exudative age-related macular degeneration (AMD) and vein occlusion at a German university eye hospital]. 2019 , 116, 553-562	1
209	Systemic side effects after intravitreal administration of anti-vascular endothelial growth factors for neovascular age-related macular degeneration. 2019 , 33, 110-116	

208	OCT Risk Factors for Development of Late Age-Related Macular Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study. <i>Ophthalmology</i> , 2019 , 126, 1667-1674	7-3	47
207	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. 2019 , 12, 1756286419878324		31
206	One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. 2019 , 2019, 7530458		5
205	Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. 2019 , 137, 372-379		59
204	Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. 2019 , 19, 735-751		13
203	The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. <i>Ophthalmology</i> , 2019 , 126, 1141-1154	7-3	128
202	Imaging, Genetic, and Demographic Factors Associated With Conversion to Neovascular Age-Related Macular Degeneration: Secondary Analysis of a Randomized Clinical Trial. 2019 , 137, 738-744		15
201	Updated Methods for Assessing the Risk of Progression to Late Age-Related Macular Degeneration. 2019 , 137, 745-746		
200	Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and the Ugly: The LXXV Edward Jackson Memorial Lecture. 2019 , 204, 26-45		6
199	Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part I: A Review of Disease Characterization and Morphological Associations. 2019 , 8, 235-249		9
198	Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease: One-Year Results of the Randomized Canadian Treat-and-Extend Analysis Trial with Ranibizumab Study. <i>Ophthalmology</i> , 2019 , 126, 841-848	7-3	39
197	Simulating an Anti-Vascular Endothelial Growth Factor Switch in Neovascular Age-Related Macular Degeneration: A HARBOR Subanalysis. <i>Ophthalmology</i> , 2019 , 126, 849-855	7-3	6
196	Geriatric Ophthalmology. 2019 ,		1
195	Age-Related Macular Degeneration: Clinical Management. 2019 , 53-66		
194	Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review. 2019 , 4, e000398		38
193	Treat-and-extend regimens with anti-vascular endothelial growth factor agents in age-related macular degeneration. 2019 , 14, 287-307		1
192	Predictors of neovascular activity during neovascular age-related macular degeneration treatment based on optical coherence tomography angiography. 2019 , 9, 19240		10
191	Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results. <i>Ophthalmology</i> , 2019 , 126, 723-734	7-3	116

190	[Pro re nata anti-VEGF treatment results for neovascular age-related macular degeneration in routine clinical treatment: comparison of single with triple injections]. 2019 , 116, 441-446		1
189	COMBINATION THERAPY OF INTRAVITREAL RANIBIZUMAB AND SUBTHRESHOLD MICROPULSE PHOTOCOAGULATION FOR MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION: 6-MONTH RESULT. 2019 , 39, 1377-1384		15
188	HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolocizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020 , 127, 72-84	7.3	278
187	[An Illustrated Guidance for the Implementation of Methodological CONSORT Criteria in the Transparent Publication of RCTs in Ophthalmology]. 2020 , 237, 681-688		
186	Spectral-Domain OCT-Based Prevalence and Progression of Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020 , 127, 523-532	7.3	13
185	Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?. 2020 , 4, 141-147		5
184	Visual Acuity Outcomes and Anti-Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes. 2020 , 4, 19-30		49
183	Twelve per cent of 6142 eyes treated for neovascular age-related macular degeneration (nAMD) presented with low visual outcome within 2 years. Analysis from the Swedish Macula Registry (SMR). 2020 , 98, 274-278		5
182	A Review of Macular Atrophy of the Retinal Pigment Epithelium in Patients with Neovascular Age-Related Macular Degeneration: What is the Link? Part II. 2020 , 9, 35-75		4
181	Age-Related Macular Degeneration Preferred Practice Pattern. <i>Ophthalmology</i> , 2020 , 127, P1-P65	7.3	76
180	Nonresponders to Ranibizumab Anti-VEGF Treatment Are Actually Short-term Responders: A Prospective Spectral-Domain OCT Study. 2020 , 4, 1138-1145		10
179	Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. 2020 , 243, 1-8		27
178	MACULAR ATROPHY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Pilot Post Hoc Analysis of Patients With Pigment Epithelial Detachments. 2020 , 40, 266-272		3
177	MORPHOLOGICAL AND FUNCTIONAL CHARACTERISTICS AT THE ONSET OF EXUDATIVE CONVERSION IN AGE-RELATED MACULAR DEGENERATION. 2020 , 40, 1070-1078		9
176	EVALUATION OF SURGICAL FACTORS AFFECTING VITREOUS HEMORRHAGE FOLLOWING PORT DELIVERY SYSTEM WITH RANIBIZUMAB IMPLANT INSERTION IN A MINIPIG MODEL. 2020 , 40, 1520-1528		13
175	Prevalence and characteristics of macular atrophy in eyes with neovascular age-related macular degeneration. A study from a long-term observational dataset: the Fight Retinal Blindness! project. 2020 , 104, 1064-1069		3
174	Meticulous multimodal analysis of aflibercept therapy for submacular vascularized pigment epithelial detachment associated with neovascular AMD in a prospective case series, the EVEN study. 2020 , 20, 100916		0
173	Management Strategies and Visual Results for the Treatment of Neovascular Age-Related Macular Degeneration. 2020 ,		0

172	Development of Deep Learning Models to Predict Best-Corrected Visual Acuity from Optical Coherence Tomography. 2020 , 9, 51	4
171	Agreement of Spectral-Domain OCT with Fluorescein Leakage in Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study. 2020 , 4, 1054-1058	3
170	PREDICTORS OF RECURRENT EXUDATION IN CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION DURING A TREATMENT-FREE PERIOD. 2020 , 40, 2158-2165	4
169	Beyond antibodies: ankyrins and DARPins. From basic research to drug approval. 2020 , 51, 93-101	9
168	Detrimental Effect of Delayed Re-treatment of Active Disease on Outcomes in Neovascular Age-Related Macular Degeneration: The RAMPS Study. 2020 , 4, 871-880	9
167	End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration. 2021 , 5, 775-787	18
166	Unbiased identification of novel subclinical imaging biomarkers using unsupervised deep learning. 2020 , 10, 12954	8
165	Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19. 2020 , 258, 2639-2645	11
164	Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidence. 2021 , 105, 1475-1479	8
163	Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy. 2020 ,	10
162	Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. 2020 , 138, 955-963	29
161	Reply. 2020 , 4, e11-e12	
160	Re: Patel et al: Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?. 2020 , 4, e11	1
159	Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis. 2020 , 11, 2040622320953349	7
158	Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study. 2020 , 9, 993-1002	0
157	Use of Imaging Modalities in Real Life: Impact on Visual Acuity Outcomes of Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration in Germany. 2020 , 2020, 8024258	3
156	[Impact of a more stringent organization of intravitreal injection treatment on the number of treatments and examinations in routine practice]. 2021 , 118, 1134-1139	1
155	Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study. 2020 , 14, 3599-3610	0

154	Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. 2020 , 21,		20
153	Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. 2020 , 5, CD012208		21
152	Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab. 2020 , 4, 760-766		1
151	Definition of indicators of appropriateness in the management of neovascular age-related macular degeneration: An expert opinion. 2020 , 30, 795-804		1
150	Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records. <i>Ophthalmology</i> , 2020 , 127, 1179-1188	7-3	11
149	Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography. 2020 , 138, 740-747		38
148	Building on the success of anti-vascular endothelial growth factor therapy: a vision for the next decade. 2020 , 34, 1966-1972		16
147	End-to-End Deep Learning Model for Predicting Treatment Requirements in Neovascular AMD From Longitudinal Retinal OCT Imaging. 2020 , 24, 3456-3465		10
146	Patient Preferences for Anti-Vascular Endothelial Growth Factor Treatment for Wet Age-Related Macular Degeneration in Japan: A Discrete Choice Experiment. 2020 , 14, 553-567		7
145	Long-Term Visual/Anatomic Outcome in Patients with Fovea-Involving Fibrovascular Pigment Epithelium Detachment Presenting Choroidal Neovascularization on Optical Coherence Tomography Angiography. 2020 , 9,		3
144	Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration in routine clinical practice in France: results from the RAINBOW study. 2020 , 5, e000377		1
143	Post-hoc analysis of single nucleotide polymorphism profile for eyes with vascularized pigment epithelial detachment due to ARMD. 2021 , 31, 1281-1290		0
142	Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice. 2020 , 6, 9		3
141	ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD). 2020 , 104, 1573-1578		8
140	Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema. 2020 , 26, 253-266		7
139	Three-year follow-up of choroidal neovascularisation in eyes of chronic central serous chorioretinopathy. 2020 , 104, 1561-1566		3
138	Seven-Year Visual and Anatomical Outcomes of Intravitreal Vascular Endothelial Growth Factor Inhibition for Neovascular Age-Related Macular Degeneration. 2020 , 2020, 8345850		2
137	Comparison of the Efficacy of Brolucizumab with Natural Disease Progression in Wet AMD Using Clinical Data from the Phase III HAWK and HARRIER Trials and Modelled Placebo Data. 2020 , 45, 1298-1301		4

136	OCT Angiography Features of Neovascularization as Predictive Factors for Frequent Recurrence in Age-Related Macular Degeneration. 2020 , 213, 109-119		11
135	Association of Visit Adherence and Visual Acuity in Patients With Neovascular Age-Related Macular Degeneration: Secondary Analysis of the Comparison of Age-Related Macular Degeneration Treatment Trial. 2020 , 138, 237-242		18
134	Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration - results from the randomized, phase IIIb OCTAVE study. 2020 , 20, 18		4
133	Sustained delivery of acriflavine from the suprachoroidal space provides long term suppression of choroidal neovascularization. 2020 , 243, 119935		12
132	Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes. 2020 , 216, 165-173		11
131	Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020 , 127, 1211-1219	7:3	41
130	Prediction of OCT images of short-term response to anti-VEGF treatment for neovascular age-related macular degeneration using generative adversarial network. 2020 , 104, 1735-1740		10
129	Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2020 , 127, 1360-1370	7:3	16
128	Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits. 2020 , 9, 7		5
127	Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolocizumab administrations. 2020 , 18, 100687		35
126	Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study. <i>Ophthalmology</i> , 2020 , 127, 1331-1344	7:3	39
125	HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolocizumab for Neovascular Age-Related Macular Degeneration. <i>Ophthalmology</i> , 2021 , 128, 89-99	7:3	73
124	Retinal pigment epithelial characteristics in eyes with neovascular age-related macular degeneration : Long-term retinal changes under anti-vascular endothelial growth factor treatment. 2021 , 133, 123-130		1
123	Quantitative Analysis of OCT for Neovascular Age-Related Macular Degeneration Using Deep Learning. <i>Ophthalmology</i> , 2021 , 128, 693-705	7:3	19
122	Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities. 2021 , 82, 100906		27
121	Resident physician concordance in tomographic fluid detection in nīve patients with neovascular age-related macular degeneration (AMD). 2021 , 96, 236-241		
120	Age-Related Macular Degeneration Revisited: From Pathology and Cellular Stress to Potential Therapies. 2020 , 8, 612812		13
119	Mingjing granule, a traditional Chinese medicine in the treatment of neovascular age-related macular degeneration: study protocol for a randomized controlled trial. 2021 , 22, 69		0

118	Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. 2021 , 24, 1087-1097	
117	Autotranslocation of the pigment epithelium-choroid complex in treatment of age-related macular degeneration scarring stage. 2020 , 13, 97-104	
116	Ocular Imaging for Enhancing the Understanding, Assessment, and Management of Age-Related Macular Degeneration. 2021 , 1256, 33-66	1
115	Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials. 2021 , 11, e040906	2
114	Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration. 2021 , 21, 90	4
113	Changes in Treatment-Naive Pigment Epithelial Detachments Associated With the Initial Anti-Vascular Endothelial Growth Factor Injection: A Post Hoc Analysis From the HARBOR Trial. 2021 , 139, 219-223	2
112	Impact of Delayed Time to Treatment on Visual Outcomes in Neovascular AMD: Data From the HARBOR Study. 2021 , 52, 62-69	0
111	Longitudinal Higher-Order OCT Assessment of Quantitative Fluid Dynamics and the Total Retinal Fluid Index in Neovascular AMD. 2021 , 10, 29	4
110	Spatio-temporal alterations in retinal and choroidal layers in the progression of age-related macular degeneration (AMD) in optical coherence tomography. 2021 , 11, 5743	4
109	Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study. 2021 , 99, 861-870	2
108	Safety and efficacy of Razumab (world's first biosimilar ranibizumab) in wet age-related macular degeneration: a post-marketing, prospective ASSET study. 2021 , 7, 24	2
107	IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN. 2021 , 41, 2221-2228	6
106	Importance of Anatomical Efficacy for Disease Control in Neovascular AMD: An Expert Opinion. 2021 , 10, 231-243	0
105	Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options. 2021 , 10,	13
104	The RAP study, report 3: Discoloration of the macular region in patients with macular neovascularization type 3. 2021 ,	2
103	Resident physician concordance in tomographic fluid detection in nīve patients with neovascular age-related macular degeneration (AMD). 2021 , 96, 236-241	
102	RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. 2021 , 41, 1579-1586	2
101	Application of machine learning methods to bridge the gap between non-interventional studies and randomized controlled trials in ophthalmic patients with neovascular age-related macular degeneration. 2021 , 104, 106364	5

100	Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy. 2021,	2
99	Anti-VEGF Treatment Patterns in Patients With Wet Age-Related Macular Degeneration in Clinical Practice. 2021, 52, 263-272	
98	Evaluation of Long-Lasting Potential of Suprachoroidal Axitinib Suspension Via Ocular and Systemic Disposition in Rabbits. 2021, 10, 19	0
97	Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography. 2021, 11,	1
96	Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions. 2021, 16, 267-286	
95	THE RELATIONSHIP BETWEEN STOPPER POSITION AND INJECTION VOLUME IN RANIBIZUMAB AND AFLIBERCEPT PREFILLED SYRINGES. 2021, 41, 2510-2514	1
94	One-year Outcomes of a Treat-and-extend of Ranibizumab for Naive Exudative Age-related Macular Degeneration: Retrospective Analysis. 2021, 62, 939-947	
93	Long-Term Analysis of Clinical Features and Treatment Outcomes of Inflammatory Choroidal Neovascularization. 2021, 233, 18-29	0
92	Artificial intelligence-based predictions in neovascular age-related macular degeneration. 2021, 32, 389-396	2
91	Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. 2021, 259, 3665-3673	1
90	Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration. 2021, 233, 8-17	2
89	Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial. 2021, 1	0
88	Predictors of Visual Acuity After Treatment of Neovascular Age-Related Macular Degeneration - Current Perspectives. 2021, 15, 3351-3367	0
87	Beyond the Visual Acuity: Assessing the Visual Function in mCNV Patients After Anti-VEGF Treatment. 2021, 8, 709584	
86	Prechoroidal cleft thickness correlates with disease activity in neovascular age-related macular degeneration. 2021, 1	
85	Complications associated with worse visual outcomes in patients with exudative neovascular age-related macular degeneration. 2021,	0
84	To the Question of Terminology, Expert Criteria for Evaluating the Effectiveness of Antiangiogenic Therapy and the Prevalence of Refractory Forms of Neovascular Age-Related Macular Degeneration. Review. 2021, 18, 389-398	0
83	Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. 2021, 13,	25

82	ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR DOSING AND EXPECTED ACUITY OUTCOME AT 1 YEAR. 2021 , 41, 1153-1163	2
81	Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. 2021 , 139, 68-76	16
80	Pharmacokinetics of Intravitreally Applied VEGF Inhibitors. 2016 , 139-148	1
79	QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY FEATURES OF INACTIVE MACULAR NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION. 2021 , 41, 93-102	3
78	Recent developments in the treatment of age-related macular degeneration. 2014 , 124, 1430-8	118
77	[A differentiated approach to analysis of retinal fluid and assessment of its effect on anti-VEGF therapy of neovascular age-related macular degeneration]. 2019 , 135, 134-140	2
76	Anti-vascular Endothelial Growth Factor Outpatient Treatment Patterns in Patients with Exudative Age-related Macular Degeneration from a Japanese Hospital Claims Database. 2014 , 2, 41-52	4
75	SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. 2013 , 44, 121-6	19
74	Clinical monitoring of patients with age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. 2014 , 45, 285-91	8
73	Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials. 2016 , 23, 27-37	19
72	Inflammatory Factors of Macular Atrophy in Eyes With Neovascular Age-Related Macular Degeneration Treated With Aflibercept. 2021 , 12, 738521	2
71	Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes. 2021 ,	3
70	Associations and outcomes of patients with submacular haemorrhage secondary to age-related macular degeneration in the IVAN trial. 2021 ,	1
69	Glaucoma. 2017 ,	
68	Whither (or Wither) Adherence to Retina Trial Protocols in Clinical Practice?. 2017 , 48, 692-698	1
67	Pharmacological Analysis of Resistance to Anti-VEGF Therapy. 2019 , 15, 382-387	0
66	Management Strategies for Neovascular AMD. 2020 , 99-108	
65	Two different treatment regimens of ranibizumab 0.5[mg for neovascular age-related macular degeneration with or without polypoidal choroidal vasculopathy in Chinese patients: results from the Phase IV, randomized, DRAGON study. 2021 , 99, e336-e345	1

64	MANAGEMENT OF RETINAL PIGMENT EPITHELIUM TEAR DURING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 2021 , 41, 671-678	1
63	Association between Ranibizumab Injections and Risk of Acute Myocardial Infarction in Age-related Macular Degeneration: A Case-crossover Study. 2020 , 34, 150-157	2
62	[Anti-VEGF therapy for neovascular age-related macular degeneration: causes of incomplete response]. 2021 , 137, 152-159	0
61	Clinical Trials Related to Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. 2020 , 259-281	0
60	Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. 2020 , 48, 408-419	1
59	Visual Outcome and Treatment Frequency of Anti-VEGF Therapy Using the Treat-and-Extend and Treatment Cessation Regimen for Exudative Age-Related Macular Degeneration and Pachychoroid Neovascularopathy. 2021 , 15, 4405-4418	0
58	Age-related macular degeneration: anti-vascular endothelial growth factor treatment. 2016 , 2016,	6
57	Anti-vascular endothelial growth factor indications in ocular disease. 2015 , 59, 235-242	14
56	The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration. 2019 , 63, 238-244	1
55	Factors for Visual Acuity Improvement After Anti-VEGF Treatment of Wet Age-Related Macular Degeneration in China: 12 Months Follow up. 2021 , 8, 735318	0
54	TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration. 2021 , 100076	2
53	Treatment patterns and outcomes with anti-vascular endothelial growth factor agents for wet age-related macular degeneration in clinical practice: an analysis of the IRIS Registry. 2021 ,	1
52	Comparison of agents using higher dose anti-VEGF therapy for treatment-resistant neovascular age-related macular degeneration.. 2022 , 1	0
51	Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.. 2022 ,	15
50	Managing Neovascular Age-Related Macular Degeneration in Clinical Practice: Systematic Review, Meta-Analysis, and Meta-Regression.. 2022 , 11,	1
49	Aqueous proteins help predict the response of neovascular age-related macular degeneration patients to anti-VEGF therapy. 2021 ,	0
48	From data to deployment: the Collaborative Communities on Ophthalmic Imaging roadmap for artificial intelligence in age-related macular degeneration.. <i>Ophthalmology</i> , 2022 ,	7:3 0
47	LRG1 as a novel therapeutic target in eye disease.. 2022 ,	2

- 46 Disease Progression Pathways of Wet AMD: Opportunities for New Target Discovery.. **2022**, 0
- 45 Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept.. **2022**, 8, 11
- 44 Ranibizumab and Neovascular Age-related Macular Degeneration. **2021**, 15, 55
- 43 Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV.. **2022**, 12, 2993 0
- 42 Utilization of deep learning to quantify fluid volume of neovascular age-related macular degeneration patients based on swept-source OCT imaging: The ONTARIO study.. **2022**, 17, e0262111 0
- 41 A model to quantify the influence of treatment patterns and optimize outcomes in nAMD.. **2022**, 12, 2789 0
- 40 Fluctuations in central foveal thickness and association with vision outcomes with anti-VEGF therapy for nAMD: HARBOR post hoc analysis.. **2022**, 7, e000957
- 39 Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR.. **2022**, 1 1
- 38 One-year outcome of neovascular age-related macular degeneration patients followed-up using different optical coherence tomography modalities.. **2022**, 11206721221088260
- 37 Generation of a Porcine Antibody Fab Fragment Using Protein Engineering to Facilitate the Evaluation of Ocular Sustained Delivery Technology.. **2022**,
- 36 Impact of intra- and subretinal fluid on vision based on volume quantification in the HARBOR trial.. **2021**, 1
- 35 A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk.. **2022**, 12, 5574 0
- 34 A systematic correlation of central subfield thickness (CSFT) with retinal fluid volumes quantified by deep learning in the major exudative macular diseases.. **2021**, 2
- 33 Efficacy and Safety of Anti-Vascular Endothelial Growth Factor Monotherapies for Neovascular Age-Related Macular Degeneration: A Mixed Treatment Comparison.. **2021**, 12, 797108 2
- 32 Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy.. **2022**, 14, 25158414221083363
- 31 Prevalence and Progression of Macular Atrophy in Eyes with Neovascular Age-Related Macular Degeneration in the Phase 2 Ladder Trial of the Port Delivery System with Ranibizumab.. **2022**,
- 30 Polymer based sustained drug delivery to the ocular posterior segment: barriers and future opportunities for the treatment of neovascular pathologies.. **2022**, 114342 5
- 29 Drusen Characteristics and Age-Related Macular Degeneration in Fellow Eyes. **2022**, 0

28	Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis. 2022 ,	1
27	Effect of Alcohol on Vascular Endothelial Growth Factor Expression in Retinal Pigment Epithelium Cells and Angiogenesis. 2022 , 7, 1-8	
26	Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.	1
25	Morphology of en face Haller vessel and macular neovascularization at baseline and 3 months as predictive factors in age-related macular degeneration. 2022 , 12,	
24	Predicting Visual Acuity in Patients Treated for AMD. 2022 , 12, 1504	
23	Age-related Macular Degeneration patient deep phenotyping and whole genome sequencing analysis identifies coding variants linking small low-luminance visual deficit to fat storage defects.	
22	Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration.	1
21	Predicting treat-and-extend outcomes and treatment intervals in neovascular age-related macular degeneration from retinal optical coherence tomography using artificial intelligence. 9,	
20	Factors associated with the recurrence of choroidal neovascularization in pathologic myopia. 9,	0
19	Macular Atrophy Incidence, Progression, and Visual Acuity Effects in 5-Year Treatment of Neovascular Age-Related Macular Degeneration. 2022 , 53, 546-552	0
18	Effect of Ranibizumab and Aflibercept on Retinal Pigment Epithelial Detachment, Subretinal, and Intra-Retinal Fluid in Age-Related Macular Degeneration. 2022 , 78, 176-185	0
17	Aflibercept is more effective than bevacizumab at weaning neovascular age-related macular degeneration patients off therapy.	0
16	Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons. Volume 16, 4273-4279	0
15	Cost impact of different treatment regimens of brodalumab in neovascular age-related macular degeneration: A budget impact analysis. 2022 , 28, 1350-1364	0
14	Relevance of Visual Acuity Measurement for Therapeutic Decisions in Age-Related Macular Degeneration. 2023 , 12, 522	0
13	Sample size calculation for clinical trials analyzed with the meta-analytic-predictive approach.	0
12	The Role Of HTRA Serine Peptidase 1, Vascular Endothelial Growth Factor and Tumor Necrosis Factor Gene Polymorphisms in the Treatment Of Wet Age-Related Macular Degeneration. 2023 , 3-4, 45-53	0
11	Implementing Predictive Models in Artificial Intelligence through OCT Biomarkers for Age-Related Macular Degeneration. 2023 , 10, 149	0

- 10 Sustained Biweekly Aflibercept For Refractory Neovascular Age-Related Macular Degeneration: The Prospective TRISTAR Study. **2022**, Publish Ahead of Print, ○
- 9 STRICT PRO RE NATA VERSUS TREAT-AND-EXTEND REGIMENS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. **2023**, 43, 420-432 ○
- 8 PATTERNS OF SUBRETINAL AND/OR INTRARETINAL FLUID RECURRENCE IN PATIENTS WHO RECEIVED AS-NEEDED RANIBIZUMAB THERAPY IN THE HARBOR TRIAL. **2023**, 43, 624-631 ○
- 7 High-Dose Aflibercept for Neovascular AMD and DME in Suboptimal Responders to Standard-Dose Aflibercept. **2023**, 7, 116-124 ○
- 6 Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis. ○
- 5 Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results. **2023**, ○
- 4 Common retinal disorders. **2018**, 413-435 ○
- 3 Age-related macular degeneration. **2023**, ○
- 2 Rare CIDEC coding variants enriched in age-related macular degeneration patients with small low-luminance deficit cause lipid droplet and fat storage defects. **2023**, 18, e0280484 ○
- 1 Machine Learning to Predict Response to Ranibizumab in Neovascular Age-Related Macular Degeneration. **2023**, 100319 ○